The AI Manuscript Flood: What the 2026 Submission Surge Means for Legitimate Medical Authors

Medical journals were already under pressure before AI writing tools became mainstream. Reviewer pools were thinning, submission volumes were climbing, and time-to-first-decision at selective journals had stretched well past three months. Then, starting in late 2022, generative AI made it markedly easier to produce manuscripts that look finished from the outside. The submission surge that followed has changed the environment that legitimate clinical researchers submit into, often without their realizing it.

The numbers coming out of publishing infrastructure platforms in 2026 are striking. Journals on the ScholarOne Manuscripts platform, which handles submission workflows for thousands of peer-reviewed titles including major medical journals, received 33% more submissions in the first quarter of 2026 than in the same period of 2025. That year-over-year growth rate more than doubled compared to the prior year: journals had seen roughly 17% growth in 2025 over 2024. The acceleration is not slowing.

Global scholarly output is projected to cross six million articles in 2026, up from an estimated 5.5 million in 2025. Total submissions across platforms are reportedly up 56% since the release of ChatGPT in late 2022. These are ecosystem-level shifts, not fluctuations. They have real consequences for how long your manuscript waits, how much editorial attention it receives before a decision, and what it now takes to clear desk review at the journals that matter most to your career.

What the Data Actually Shows

The most rigorous analysis of AI's effect on academic submissions comes from an editorial study published in Organization Science in 2026. The editors analyzed 6,957 submissions by 11,887 authors, reviewed 10,389 times by 2,519 unique reviewers over a five-year window. They used Pangram, a transformer-based AI content detector optimized for adversarial paraphrasing, to score manuscripts by the proportion of AI-generated text.

Several findings stand out. Submissions to the journal rose 42% between November 2022 and February 2026, roughly double the increase seen during the COVID-19 pandemic period, and the editors attribute nearly all of the post-ChatGPT growth to AI. The fastest-growing category of submission was papers scored at 70% or higher AI-generated content. The share of human-only manuscripts, those showing negligible AI involvement, actually declined over the same period.

What happened to writing quality? It fell. The Flesch Reading Ease score, a standard measure of prose accessibility, was 1.28 standard deviations lower in January 2026 compared to January 2021. AI-assisted manuscripts were harder to read, more jargon-laden, and, by the time they reached reviewers, more likely to be rejected than their human-written counterparts. The tool that authors were using to speed up submission was also making their papers worse.

A separate bioRxiv preprint published in 2026 analyzed full-length research articles from 13 major journals using the same Pangram detector. Papers published in 2021 through 2024 showed almost no detectable AI-generated text. Manuscripts published in 2025 showed a sharp increase: 12.4% contained at least one passage classified as AI-written. The distribution was skewed by geography. Roughly 32% of papers from South Korean institutions and 26% from Chinese institutions contained AI-generated passages, compared to 7.4% from U.S. institutions. Those numbers presumably reflect a combination of real AI use and the tendency of AI detection tools to flag text written by non-native English speakers, a methodological limitation worth noting.

Who Is Driving the Surge

Not all the new submissions come from researchers trying to cut corners. AI writing assistance is genuinely useful to researchers working in a second or third language, to clinicians who have strong scientific instincts but weaker prose habits, and to early-career researchers still learning the conventions of academic writing. Surveys from 2026 put adoption of AI tools for writing and publication tasks at 58% to 62% of researchers, up from around 45% in 2024. These are not all bad-faith actors.

But the structural pattern is telling. The journals that saw the largest proportional increases in submission volume in Q1 2026 were not the flagship journals where editors have the most resources. Journals receiving fewer than 15 submissions per quarter in 2025 saw an 81% surge by Q1 2026. Journals receiving more than 1,500 submissions per quarter saw 20% growth. The flood is hitting smaller, less-resourced journals hardest, and many of those journals serve specialty medical disciplines where peer reviewer pools are already thin.

Research teams from institutions under strong publish-or-perish incentive structures are overrepresented in the surge. When output metrics drive academic careers and promotions, and when a tool exists that reduces the friction of getting a manuscript to submission stage, the incentive calculus changes. This is not unique to one country or discipline. It is a global response to a specific kind of productivity pressure.

The Reviewer Crisis Gets Worse

The submission surge is colliding with a reviewer system already under strain. Silverchair, which now owns ScholarOne, published its 2026 Future of Peer Review report drawing on eight years of platform activity, a literature review, expert interviews, and surveys of more than 2,000 reviewers, authors, and editors. The findings are sobering.

The global reviewer pool grew 54% between 2018 and 2025, so there are more potential reviewers than ever. But the rate at which those reviewers accept invitations has fallen sharply. Editors now need an average of 4.5 invitations to secure a single completed review, nearly double the rate from 2018. Per 100 invitations sent, editors wait a combined 407 days for responses from reviewers who ultimately decline or do not reply. That is more than a year of accumulated waiting, burned on people who never reviewed the paper.

When you add a 33% submission increase on top of a reviewer base that is already turning down half its invitations, the math becomes unfavorable for authors waiting on decisions. Editors cannot simply expand the reviewer pool fast enough to absorb that volume. The response, which editors are sometimes reluctant to say out loud, is to screen harder before papers ever reach reviewers. Desk rejection rates at many journals are rising not because editorial standards changed but because the editorial filter is now doing more work at an earlier stage.

What Journals Are Doing About It

Publishers are deploying a range of screening tools to manage the surge before papers reach human reviewers. Springer Nature, JMIR Publications, and Wiley have implemented AI-supported submission screening. The Royal Society of Chemistry partnered with Enago for AI-powered manuscript checks earlier in 2026. These systems typically run several checks in parallel: iThenticate flags text overlap and duplicate submissions, SciScore assesses whether key methodological elements (antibody identifiers, cell line authentication, statistical reporting, ethics approvals) are correctly reported, and newer tools evaluate AI content probability alongside image integrity.

The AI detection component is the weakest link in this chain, and editors know it. Current detectors work on probabilities derived from text patterns. They are not reliable enough to trigger rejection on their own, and they produce false positives at rates that would be unfair to non-native English writers who tend to produce more formal, structured prose that can score AI-like. No responsible editor is using a single AI detection score as a rejection criterion. But when a detection flag combines with other signals, such as a fabricated reference, a suspicious authorship pattern, or inconsistencies in the reported data, the combination changes the editorial calculation.

Journals are also responding by tightening their actual manuscript requirements. Several publishers have added mandatory structured reporting checklist submissions for paper types that previously handled them informally. A few have begun requiring authors to complete a brief verification of methodology in the submission portal before the manuscript reaches an editor. These are friction-adding measures, but their purpose is partially to deter low-effort submissions that would not survive the checklist exercise.

The Quality Paradox for Authors Using AI

One finding from the Organization Science data is worth dwelling on, because it has direct implications for authors. AI-generated manuscripts were not just more likely to be rejected. They were harder for reviewers to read. They were more jargon-laden. They tended to use the kind of elaborate throat-clearing that characterizes generated prose: long introductory sentences that qualify every claim, strings of abstract nouns, passive constructions stacked two deep. The irony is that the tool being used to speed up drafting was simultaneously producing prose that reviewers found harder to engage with.

This matters even for authors who are using AI legitimately, as a polishing tool rather than a drafting engine. If a manuscript has been passed through a language model to improve flow, the output often acquires the stylistic fingerprints of generated text even when the underlying ideas are entirely the author's own. The result can be a paper that reads well enough at a glance but feels oddly distant and imprecise, the kind of prose that makes reviewers work harder without knowing exactly why.

The practical implication is that authors who want to use AI tools responsibly should use them on drafts, then revise the output rather than accepting it. A generated paragraph that gets read aloud to a colleague and then edited for the parts that sound wrong will generally survive a reviewer better than a generated paragraph that was checked only for grammar. This is more work than it sounds, but it is also closer to what genuine editing has always meant.

What the Flood Means If Your Paper Is Real

If you are preparing a genuine clinical study, a well-designed retrospective analysis, or a systematic review that took two years to complete, the submission surge is unfair to you in a specific way. Your paper is competing for editorial attention alongside a much larger volume of thin submissions. The editors who scan your title page and abstract for those first ten seconds are doing it with more manuscripts in queue than ever, under more time pressure, with reviewer capacity that has not kept up. The bar for what catches attention has raised, not because your science got worse but because the noise floor around it got louder.

Several things are worth doing before you submit, and some of them are different from what they were three years ago.

The abstract is now more important than it has ever been. Editors at selective journals are spending less time on initial reads, not more. An abstract that buries the main finding, or that uses vague outcome language, or that does not specify the population and follow-up period, will not give the editor much reason to send the paper out. Frontload the finding. State the population, the design, the primary outcome, and the result in the first three sentences. Leave the context for the introduction.

Reporting standard checklists are your pre-screening pass. A clinical trial needs a completed CONSORT 2025 checklist. An observational study needs STROBE. A systematic review needs PRISMA 2020. These are not administrative extras. They are what the automated screening systems are checking before a human sees the paper. A manuscript that arrives with complete checklists passes through automated triage more quickly, and it signals to the editor on first read that the authors know what they are doing.

Reference verification has become a practical necessity. The Lancet published a research letter in May 2026 documenting a 12-fold rise in fabricated citations in PubMed-indexed papers between 2023 and early 2026. Journals that have identified this as a systematic risk are screening references. If an automated check pulls a citation from your list and returns a DOI mismatch, the submission is flagged. Verifying every reference in your list against its actual record is not paranoia; it is now one of the baseline steps in legitimate manuscript preparation.

The Disclosure Question in a Flooded Market

There is a specific temptation created by the current environment that is worth naming. Because AI-generated manuscripts are attracting editorial scrutiny, some authors who used AI tools legitimately, for language polishing or translation, are wondering whether to leave that use out of the disclosure to avoid triggering any extra review. This is the wrong calculation.

Editors in 2026 are not automatically suspicious of AI disclosure. What makes them suspicious is a manuscript that reads like it was AI-generated but carries no disclosure. A candid acknowledgement that you used a language tool to improve the English in the discussion section, followed by a statement that the authors reviewed and verified all content, is unremarkable. It is the right thing to say, and it is what the ICMJE January 2026 update now formally requires.

The risk of omitting a disclosure is asymmetric. If you disclose and the editor has no concerns, nothing changes. If you do not disclose and something in the manuscript later triggers a post-publication check, the missing disclosure becomes evidence of a coverup rather than just a use of a writing tool. The reputational cost of that sequence is substantially higher than the minor friction of the disclosure itself.

Targeting Your Journal Differently Now

The submission surge changes the logic of tiered submission strategies in ways that are not obvious. The conventional wisdom was to start high and work down: submit to NEJM, get rejected, submit to JAMA, and so on until you find the right level. That strategy still works, but the slope has gotten steeper and the steps are further apart.

At the very top, the flagship journals (New England Journal of Medicine, The Lancet, JAMA, BMJ, Nature Medicine) have always rejected the large majority of submissions at desk. Their desk rejection rate is not meaningfully affected by the AI surge because their standards were already high enough that most of the surge-driven volume never reaches them, or is turned away almost immediately. These journals are not harder to get into because of AI; they were already extremely selective.

The middle tier, specialty journals with impact factors in the range of three to eight, is where the submission surge is most disruptive. These journals have enough prestige to attract a large share of the AI-assisted submissions, but fewer editorial resources to process them. Review times at this tier have extended meaningfully in 2026, and some editors in this space are now making initial desk decisions within 48 hours simply to keep the queue manageable, rather than spending the time they once would have on borderline cases.

One practical response is to be more deliberate about fit before you submit. A paper that is obviously in scope for a journal, that cites recent papers from that journal, that uses the appropriate methodology for the discipline, and that matches the article type the journal publishes most often will clear an editor's first impression more reliably than a technically sound paper that looks like it was written for a different audience. In a lower-volume environment, the editor has time to see past a fit problem. In the current environment, they often do not.

Where This Is Heading

Several things seem likely over the next 12 to 18 months. Submission volumes will probably continue rising, because the underlying incentive structures that drive them have not changed. Reviewer compensation experiments, such as the Biology Open pilot that cut time-to-decision from 37.7 working days to 5.5 by paying reviewers 220 pounds per manuscript, will spread to more journals, though slowly. AI screening tools will improve enough that detection accuracy becomes a more reliable signal, but will remain probabilistic rather than certain.

The more durable change is probably in the role of the cover letter and the abstract. When editors are under time pressure and submission volumes are high, the documents that make the first impression carry more weight than they did in a lower-volume era. Authors who have treated these as formalities are going to find that changing how they write them pays off faster than changing anything about the underlying research.

There is also a reasonable case that mid-tier specialty journals will get more selective in ways that push good papers toward diamond open-access venues and preprint-first models. The cOAlition S 2026-2030 strategy explicitly supports this shift, and HHMI's requirement that researchers post a preprint before first submission gives clinical authors a way to establish priority without depending on any single journal's triage process. The submission surge is partly accelerating a structural change that was already underway.

The practical takeaway is not discouraging. The AI manuscript flood is a problem for editors and for authors submitting thin work. For a researcher with a solid clinical study and a manuscript prepared with care, the environment is harder but not closed. The checklist above, combined with an honest disclosure practice and a cover letter that actually describes the scientific contribution, still gets legitimate papers into review. It just requires more intentionality than it did three years ago.

Further Reading